Provided by Tiger Trade Technology Pte. Ltd.

Vertex Pharmaceuticals

491.47
+26.455.69%
Post-market: 494.563.09+0.63%19:58 EST
Volume:2.92M
Turnover:1.44B
Market Cap:124.70B
PE:32.08
High:503.88
Open:471.65
Low:471.65
Close:465.02
52wk High:519.68
52wk Low:362.50
Shares:253.72M
Float Shares:253.72M
Volume Ratio:1.58
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):15.32
EPS(LYR):15.32
ROE:22.54%
ROA:12.16%
PB:6.68
PE(LYR):32.08

Loading ...

Vertex, Inc. Earnings Call Highlights Cloud and AI Momentum

TIPRANKS
·
8 hours ago

Is Vertex Pharmaceuticals (VRTX) Still Attractive After Strong Multi Year Share Price Gains

Simply Wall St.
·
Yesterday

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX) and 10x Genomics (TXG)

TIPRANKS
·
Yesterday

Vertex Pharmaceuticals Inc. Stock Rallies 5.7%, Outperforms Peers

Dow Jones
·
Feb 14

Vertex Pharmaceuticals Up Over 6%, On Track for Highest Close Since May 2025 -- Data Talk

Dow Jones
·
Feb 14

Vertex Pharmaceuticals Q4 'Anticlimactic' on Pipeline, 2026 Guide Reinforces Core Strength, RBC Says

MT Newswires Live
·
Feb 14

Vertex Pharmaceuticals' Therapies for Kidney Diseases Could Diversify Long-Term Revenue Streams, Oppenheimer Says

MT Newswires Live
·
Feb 14

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EST on 2026-02-13

Reuters
·
Feb 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: Organon (OGN), Maravai Lifesciences Holdings (MRVI) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Feb 13

Vertex Pharmaceuticals price target raised to $558 from $495 at Scotiabank

TIPRANKS
·
Feb 13

Vertex Pharmaceuticals (VRTX) Receives a Buy from Evercore ISI

TIPRANKS
·
Feb 13

Stock Track | Vertex Pharmaceuticals Soars 5.21% Intraday on Multiple Analyst Upgrades Following Earnings Report

Stock Track
·
Feb 13

Morgan Stanley Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Feb 13

Vertex Pharmaceuticals : Oppenheimer Raises to Outperform From Perform

THOMSON REUTERS
·
Feb 13

Scotiabank Adjusts Vertex Pharmaceuticals PT to $558 From $495, Maintains Sector Outperform Rating

MT Newswires Live
·
Feb 13

Vertex Pharmaceuticals EVP Edward Morrow Atkinson III Reports Sale of Common Shares

Reuters
·
Feb 13

Kristen Ambrose, SVP & Chief Accounting Officer, Reports Disposal of Vertex Pharmaceuticals Common Shares

Reuters
·
Feb 13

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

Dow Jones
·
Feb 13

Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments

Reuters
·
Feb 13

Vertex Pharmaceuticals Q4 Adj. EPS $5.03 Misses $5.07 Estimate, Sales $3.190B Beat $3.176B Estimate

Benzinga
·
Feb 13